Two thirds of hematologic cancer survivors develop complications

The Spanish Society of Hematology and Hemotherapy (SEHH) organized its VIII Day of Dissemination of Information “HematoAvanza”supported by AstraZeneca, Gilead, Lilly (Gold Partners), AbbVie, BeiGene, Menarini, Novartis and Roche (Silver Partners). One of the main topics was the complications faced by hematologic cancer survivors. Possible improvements in hematologic cancers were similarly reviewed. “There’s still a long way to go achieve possible prevention of blood cancersays Maria Victoria Mateos, President of SEHH. “It is true that it does not make sense to promote screening programs for some of these cancers, but there are many others that are known to be preceded by precancerous situations in which early detection could potentially be addressed. offer follow-up and even early treatment.” However, “along with the enormous benefits that screening can bring, we must always be wary of barriers such as cost, psychological impact, or the potential need for diagnostic tools that may be unnecessary.”

Challenges for hematologic cancer survivors

“Long-term follow-up of healthy patients begins when routine cancer care ends, usuallye five years after completion of treatment, and the patient recovers,” says Izascun Zeberio from the Donostia University Hospital (Gipuzkoa). “This is very important because patients may experience late effects of the disease and/or complications resulting from their treatment that need to be prevented, diagnosed and treated effective,” the expert emphasizes about the challenges faced by hematological cancer survivors. On the other hand, other future problems were solved, this time related to CAR-T treatment. Some of them pass cover the need for large material and human resourcesreduce the cost and its economic impact on health care systems, achieve better management and prevention of toxicity that will reduce the consumption of hospital resources, and provide adequate training to medical personnel to offer this therapy to all patients who may potentially benefit.